Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

2'-Fucosyllactose Ameliorates Cognitive Impairment and Neuroinflammation in AD Mice.

Created on 30 Sep 2025

Authors

Yumeng Ma, Ming Zhang, Yutong Jin, Yifei Wang, Tengteng Ji, Fang Wu, Yixuan Li, Ran Wang, Huiyuan Guo, Fazheng Ren, Bing Fang

Published in

Journal of agricultural and food chemistry. Sep 30, 2025. Epub Sep 30, 2025.

Abstract

2'-Fucosyllactose (2'-FL) supplementation is beneficial to brain function. Our previous study has already reported the prevention of AD by 2'-FL in mice; in this study, the effects of 2'-FL in AD were evaluated. Five month-old male 5 × FAD mice were gavaged with 2'-FL for 11 weeks, and 2 mg of 2'-FL significantly improved cognitive deficits, even restoring them to the normal level. The destroyed neurons, damaged synaptic plasticity characterized by decreased cholinergic neurons and glutaminergic neurons, and the activation of microglial cells were all significantly improved by 2'-FL. 2'-FL also significantly down-regulated mRNA expression of Il-6 and Il-1β and alleviated oxidative damages through the Keap1-Nrf2 pathway to up-regulate Nqo1 expression. AD-increased PC (18:4/20:5) and DG (18:4/22:6/0:0) in the feces and serum were both decreased by 2'-FL, which was significantly positively correlated with inflammation and negatively correlated with synaptic plasticity. This study lays a theoretical basis for the application of 2'-FL in neurodegenerative diseases.

PMID:
41025716
Bibliographic data and abstract were imported from PubMed on 30 Sep 2025.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 64
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement